Director, Patient Access Liaison - East (Cell and Gene Therapy)

Location: Cambridge, Massachusetts, United States; hybrid field-based role with frequent travel across the U.S.

Salary: $225,000–$275,000 USD per year, plus performance-based bonus and equity eligibility.

Company

hirify.global develops CRISPR/Cas9 genome-editing medicines and cell therapies for severe genetic, oncological, and immunological diseases.

What you will do

• Lead, develop, and manage a high-performing team of Patient Access Liaisons across the United States.
• Translate patient access strategy into field plans, workflows, site-readiness assessments, and infusion-center activation support.
• Oversee provider education on coverage, coding, billing, prior authorization, appeals, and financial support resources.
• Partner with Hub Services, case management, payer teams, market access, medical affairs, and commercial leadership to resolve patient-specific access barriers.
• Track payer trends, denials, coverage gaps, site readiness, response times, and issue-resolution metrics through reports and dashboards.
• Support launch readiness, training curriculum, field governance, compliance, and cross-functional business reviews.

Requirements

• 10+ years of experience in field reimbursement, patient access, market access, or related biopharma or healthcare roles.
• 3–5+ years of leadership experience managing field reimbursement or access teams.
• Prior U.S. launch experience and experience with cell and gene therapy or other complex specialized therapies.
• Deep knowledge of reimbursement, coding, billing, claims processing, payer dynamics, single case agreements, and CGT access models.
• Bachelor’s degree in life sciences, business, healthcare administration, or a related field; an advanced degree is preferred.
• Frequent travel is required to support Patient Access Liaisons, sites, and cross-functional teams.

Nice to have

• Experience in rare disease and/or HAE.
• Advanced degree.

Culture & Benefits

• Patient-centric work focused on developing potentially curative genome-editing therapies.
• Performance-based annual cash bonus.
• New-hire equity grant and eligibility for annual equity awards.
• Collaborative environment centered on curiosity, innovation, accountability, and high standards.